Actively Recruiting
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
Led by Rachel Miller · Updated on 2025-06-06
93
Participants Needed
1
Research Sites
468 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a substudy (Part 2) of a larger two-part clinical trial including both observational and therapeutic (interventional) cohorts to assess the progression free survival ratio of patients treated with a targeted therapy based on genomic analysis results and recommendation by the Markey Cancer Center Molecular Tumor Board (MCC MTB).
CONDITIONS
Official Title
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with clinically suspected or histologically confirmed solid or hematological malignancy who have undergone or will undergo genetic testing of their tumor
- Patients must have failed first-line therapy for their disease (refractory) or have no options for curative therapies.
- Patients must have either measurable or non-measurable disease.
- Age 18 years.
- Eastern Cooperative Oncology Group performance status 3.
- Patients with brain metastasis must have had treatment of their brain metastasis completed at least 1 day prior to enrollment and be on stable dose of steroids or off steroids at the time of enrollment.
- Ability to understand and the willingness to sign a written informed consent document.
You will not qualify if you...
- Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with targeted therapy, in the opinion of the treating physician.
- Pregnant women are excluded from this study.
- HIV positive patients with CD4 counts below 500 OR who are not on a stable dose of antiretroviral therapy (for at least 1 month prior to registration) are ineligible.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Markey Cancer Center, University of Kentucky
Lexington, Kentucky, United States, 40536
Actively Recruiting
Research Team
R
RACHEL MILLER, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here